Participants 66 131 6
HIV-infected adults with a toll-like receptor 9 agonist adjuvant:
Participants 176 232 3
Persons infected with human immunodeficiency virus (HIV)
Participants 590 921 4
randomizing HIV-positive patients to receive double doses of 7vPnC (Prevnar) at 0 and 3 months and 1 dose of 23-valent pneumococcal polysaccharide vaccine (PPV-23; Pneumo Novum) at 9 months, with experimental patients receiving 1 mg of CPG 7909 added to each of their 3 vaccine doses; control patients had phosphate-buffered saline
Participants 1197 1250 6
Ninety-seven participants were included in the study.
